Kornimate/medical-research-clean huggingface dataset:
the effect of premedication on postoperative pain and anxiety in breast cancer surgery

Conditions: Female Patients Under the Age of 65 Who Will Undergo Breast Cancer Surgery

Summary: in this study, it was investigated whether the premedication drug administered before the surgery had an effect on postoperative pain and anxiety scores in female patients under the age of 65 who will undergo breast cancer surgery.

in this study, it was investigated whether the premedication drug administered before the surgery had an effect on postoperative pain and anxiety scores in female patients under the age of 65 who will undergo breast cancer surgery. the stai-1(state trait anxiety i̇nventory ) form and apais (amsterdam preoperative anxiety and i̇nformation scale) scale were filled in for all preoperative patients. afterwards, the patients were treated with either midazolam or dexmedetothymidine, depending on the anesthesiologist's preference. after administration, he was taken to surgery. as intraoperative analgesics, 2 mg/kg tramadol and 15 mg/kg paracetamol were administered to all patients. postoperative recovery time (aldrete 10), 1., 2.,6.,12.,24. vas score, postoperative nausea-vomiting scale, stai-1(state trait anxiety i̇nventory ) form, first need time if postoperative analgesic was needed, and 24-hour total analgesic consumption were recorded. it was aimed to examine the effects of different premedications on postoperative pain and anxiety

Eligibility criteria:
inclusion criteria: * asa 1-2-3 * 18-65 aged * female patients exclusion criteria: * under 18 years old and over 65 years old * having a history of cerebrovascular disease illiteracy * have visual and auditory problems i̇nability to cooperate with cognitive function test * having emergency surgery * those who are unable to read, understand and sign the consent form * patients deemed unsuitable by the investigator
gpc3-targeting cart cell in treatment of advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: a phase i clinical trial for evaluating the safety, tolerance and efficacy of gpc3-targeting cart cell in treatment of advanced hepatocellular carcinoma

this is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of cart cell in patients ≥ 18 years of age with relapsed or refractory advanced hepatocellular carcinoma. patients who meet the eligibility criteria will receive cell infusion. the study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment and follow up

Eligibility criteria:
inclusion criteria: 1. subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent; 2. age 18-75 years; 3. patients diagnosed as advanced hepatocellular carcinoma (hcc) histopathologically or cytologically; progression or intolerance after previous standard systemic therapy; 4. gpc3 is detected positive by immunohistochemistry (ihc); 5. child-pugh score ≤ 7; 6. at least one assessable tumor lesion; 7. ecog score: 0-1; 8. expected survival ≥ 3 months; 9. clinical laboratory values meet screening visit criteria exclusion criteria: 1. previous car-t cell, tcr-t cell or other cell therapies or therapeutic tumor vaccination directed at any target; 2. any previous gpc3 targeted therapy; 3. prior antitumor therapy with insufficient washout period; 4. brain metastases with central nervous system symptoms; 5. pregnant or lactating women 6. hcv-ab or/and hiv-ab positive; active syphilis; 7. severe underlying diseases 8. any condition that, in the opinion of the investigator, will make the subject unsuitable for participation in this study.
prevalence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure (pfo-af) study

Conditions: Patent Foramen Ovale; Atrial Fibrillation; Stroke

Summary: this study aims to assess the incidence of atrial fibrillation (af), documented using data recorded by an implantable holter monitoring device (reveal linq, medtronic) within 2 years after percutaneous closure of patent foramen ovale for cryptogenic stroke.

this study aims to assess the incidence of atrial fibrillation (af), documented using data recorded by an implantable holter monitoring device (reveal linq, medtronic) within 2 years after percutaneous closure of patent foramen ovale (pfo) for cryptogenic stroke. secondary objectives include assessment of the burden of af at 2, 12 and 24 months after pfo closure; evaluation of the relationship between plasma levels of mr proanp and presence of af within 2 years after percutaneous pfo closure in patients with a history of cryptogenic ischemic stroke; and description of recurrence rates for stroke (ischemic and hemorrhagic), major bleeding, minor bleeding, peripheral emboli during the 2-year follow-up period after percutaneous pfo closure, in patients with and without af.

Eligibility criteria:
inclusion criteria: * adult patients (aged \>18 years) * with an indication for percutaneous closure of pfo due to cryptogenic stroke, with indication validated by a cardio-neurological team. * patients must provide written informed consent * patients must be affiliated to a social security regime or be a beneficiary thereof. exclusion criteria: * patients under legal protection * patients not affiliated to any social security regime * patients within the exclusion period of another clinical trial as per the national registry of research volunteers
identification of inpatients at risk for poor glycemic control

Conditions: Hypoglycemia; Hyperglycemia

Summary: both hypoglycemia and hyperglycemia can be detrimental to hospitalized patients. however, it is not clear which patients are more likely to develop significant problems with hypoglycemia or severe hyperglycemia in the hospital. our hypothesis is that we will be able to identify risk factors present at admission that identify patients at greater risk of poor inpatient glycemic control


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * hospitalized in vuh exclusion criteria: * -length of stay \< 24 hours * pregnant women * patients receiving palliative/hospice care

Keywords: hypoglycemia among inpatients hyperglycemia among inpatients
evaluation of the screening effect of artificial intelligence hand activity evaluation system for cervical spondylosis

Conditions: 10-second G&R Test

Summary: the purpose of this study: 1. build an artificial intelligence screening tool for cervical spondylosis based on hand function analysis; 2. verify the accuracy of cervical spondylosis screening tools.

cervical spondylotic myelopathy (csm) has a high incidence in the middle-aged and elderly people. according to clinical research, the surgeon can makes a preliminary assessment of the severity of csm based on a 10-second grip and release (g\&r) test. the statistics of g\&r test mainly rely on the surgeon's manual counting. when a patient's hand motion speed is too fast, the surgeon's manual counting is prone to error, leading to potential misdiagnosis. we construct and verify the intelligent video analysis system for grip-\&-release. the system has a high accuracy and inference speed that ensure the proposed model can be used as a screening examination tool for csm and a medical assistance tool to help decision making during csm treatment planning.

Eligibility criteria:
inclusion criteria: 1. age between 18-80 years old; 2. patients who have received cervical ct or mr examination within the last month and have been clearly diagnosed or excluded from cervical spondylosis (i.e., those who have been clearly diagnosed before participating in the study); 3. people who are willing to participate in the study with ct/mr examination (i.e., those who have not been diagnosed before joining the study). exclusion criteria: 1. subjects with cervical spondylosis who have been examined but still cannot be definitively diagnosed or ruled out; 2. subjects with definite presence of hand trauma; 3. people who do not have access to ct or mr; 4. subjects who did not comply with the examination, were unable to perform neurological assessment, or were unable to fill out questionnaires.

Keywords: 10-second g&r test cervical spondylotic myelopathy hand motion analysis video analysis
response of metabolic syndrome and sexual dysfunction to lifestyle changes in men with psoriasis

Conditions: Psoriasis; Metabolic Syndrome; Erectile Dysfunction

Summary: complaint of sexual dysfunction and metabolic syndrome are highly reported in men with psoriasis

erectile dysfunction (ed) psoriatic men with metabolic syndrome (number of the patients will be 60) will assigned to study group (group = 30 patients) that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week) or control group (group=30 patients) that will receive no lifestyle changes/modifications.

Eligibility criteria:
inclusion criteria: * psoriatic married men with metabolic syndrome and erectile dysfunction exclusion criteria: * patients with heart, respiratory, other autoimmune problems
lh hormone pulsation in the luteal phase in gnrh antagonist ivf cycles triggered by gnrh agonist for final oocyte maturation

Conditions: Infertility

Summary: monitoring the lh pulsatility during the luteal phase in gnrh antagonist ivf cycles triggered by gnrh agonist for final oocyte maturation.

about two decades ago the gnrh antagonist has been used in ivf cycles to prevent premature lh surge. in recent review gnrh antagonist has been found comparable to gnrh agonist in term of live birth rate but with reduced risk of ohss. another advantage of using gnrh antagonist is the ability to use gnrh agonist for final oocyte maturation which has been shown to nearly eliminate the risk of ohss. the exact mechanism of this risk reduction is still unknown. our aim is to do a frequent blood tests every 20 minutes for 6 hours duration in the day of ovum pick up or the day of embryo transfer to measure the level of lh, estradiol and progesterone in women triggered with gnrh agonist for final oocyte maturation.

Eligibility criteria:
inclusion criteria: * age: 18-42 years old bmi \< 32 kg/m2 exclusion criteria: * hypogonadotropic hypogonadism

Keywords: luteinizing hormone pulsatility estradiol level progesterone level
tofacitinib in sars-cov2 pneumonia

Conditions: SARS-COv2 Related Interstitial Pneumonia

Summary: immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to sars-cov2 infection. tofacitinib, a jak1/3-inhibitor, could mitigate alveolar inflammation by blocking il-6 signal. the aim of this prospective single cohort open study is to test the hypotesis that early administration of tofacitinib in patients with symptomatic pneumonia could reduce pulmonary flogosis, preventing function deterioration and the need of mechanical ventilation and/or admission in intensive care units.

interstitial pneumonia is the main complication of sars-cov2 infection. immune system hyperactivation, leading to alveolar inflammation, is the main mechanism in determining lung damage. evidence are accumulating about the pivotal role played by il-6 in this disease. preliminary evidence, indeed, point out the efficacy of an il-6 receptor inhibitor in improving clinical conditions in a proportion of rapidly deteriorating patients. our hypotesis is that a precocious inhibition of il-6 signal, by the administration of tofacitinib (jak 1/3 inhibitor), could hinder the progression to more severe grades of lung inflammation leading to pulmonary function deterioration. in a prospective single cohort open study, 50 patients admitted in hospital due to sars-cov 2 symptomatic interstitial pneumonia, but not requiring mechanical ventilation, will be enrolled. tofacitinb will be administered every day for 14 days, starting within 24 h from the admission. the primary outcome is to evaluate the effect of this drug on the rate of patients who will need mechanical ventilation. safety in this population will also be actively monitored.

Eligibility criteria:
inclusion criteria: * sars-cov2 infection diagnosed by rt-pcr * rx or ct-scan confirmed interstitial pneumonia * hospital admission from less than 24h * written informed consent exclusion criteria: * age \ 65 * patients in mechanical ventilation at time of admission * severe hearth failure (nyha 3 or 4) * severe history of chronic ischemic hearth disease, defined as history of major adverse cardiovascular event and/or recent (one year) revascularization. * history of recurrent deep venous thrombosis and pulmonary embolism * active bacterial or fungal infection * hematological cancer * metastatic or intractable cancer * pre-existent neurodegenerative disease * severe hepatic impairment * severe renal failure (creatinine clearance \<30ml/h) * active herpes zoster infection * severe anemia (hb\<9g/dl) * lymphocyte count below 750/mcl * neutrophil count below 1000/mcl * platelet count below 50000/mcl * pregnancy or lactation * inability to give informed consent (severe transitory or permanent mental impairment, incapacitation)
the influence of injection speed on pain during administration of local anaesthetic.

Conditions: Needlestick Injuries

Summary: this study will investigate the influence of injection speed on pain during injection of lidocaine. it is anticipated that a longer injection time will lead to less pain for the patient during the injection. this hypothesis will be tested on healthy volunteers, who will each receive three injections with the same amount of lidocaine subcutaneously on the abdomen. the injections will be given over 15, 30 and 45 seconds. after each injection, the subject will be asked to evaluate the pain on a visual analog scale (0-100 mm). the aim of the study is to find a simple method for pain reduction that can be used in clinical practice.


Eligibility criteria:
inclusion criteria: * age 18-65 years exclusion criteria: * kidney, heart or liver disease * eczema or psoriasis on injection site * neuropathy * regular use of painkillers * hypersensitivity of lidocaine * pregnancy * diabetes

Keywords: injections time factors pain healthy volunteers lidocaine
cdc1 prognostic and predictive role in non-small-cell lung cancer patients receiving immune checkpoint inhibitors

Conditions: Non Small Cell Lung Cancer

Summary: the response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. the rare population of cdc1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. their role in humans has not been studied. this proposal aims to study the prognostic role of cdc1 in a cohort of patients with advanced nsclc, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.

multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively. the cohort will include: * 30 patients pd-l1 \> 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months * 30 patients pd-l1 \> 50% treated with pembrolizumab in first line and having a progression free survival \< 3 months * 30 patients pd-l1 \< 50% treated with cisplatin-based chemotherapy in first line

Eligibility criteria:
inclusion criteria: * nsclc diagnosis * advanced disease (stage iii-iv) according to the tnm 7th/8th classification * patients have to have performed pembrolizumab in first line if pd-l1 ≥ 50% or cisplastin-based chemotherapy if pd-l1 \< 50% * ffpe material available from diagnostic sample exclusion criteria: -
effect of hmos as nutritional support for normal bowel movements in ibs patients

Conditions: Irritable Bowel Syndrome (IBS)

Summary: this is an open labeled, one-armed real-world study in ibs-patients. all participants will receive active treatment for 12 weeks. the primary objective of the study is to assess the effect of human milk oligosaccharides (hmos) on bowel function in adults with ibs. secondary objectives are to evaluate hmos' tolerability, effect on participant reported satisfaction with bowel habits, interference with life in general, quality of life, somatic symptoms, and anxiety and depression in all patients and subgroups of patients.

in this trial, a total of 300 adults (at least 18 years of age) diagnosed with irritable bowel syndrome (ibs) in accordance with the rome iv criteria will be included. patients will be recruited from gastroenterologists and primary care clinics across the usa. the study product, fuco-n-tetraose, will be taken daily throughout the course of the trial. all data will be collected through 4 web based surveys, and the participants will complete those at baseline before the intervention starts, and after 4, 8 and 12 weeks of intake of the study product. the primary outcome of the study will be assessed by the patients' global impression of change (pgic) scale. other questionnaires used in the study includes the ibs specific gastrointestinal symptom rating scale (gsrs-ibs), the ibs quality of life scale (ibs-qol), the participant health questionnaire-4 (phq-4), the participant health questionnaire-12 (phq-12), and the bristol stool form scale (bsfs). all outcomes will be evaluated in all patients and in sub-groups of patients. i.e. subtypes by predominant bowel habit (diarrhea-predominant, constipation-predominant, or altered/mixed pattern), and lactose intolerant patients.

Eligibility criteria:
inclusion criteria: 1. ability to give oral and written informed consent 2. age minimum 18 years at enrolment 3. current clinical diagnosis of ibs from a healthcare provider, and meeting rome iv ibs diagnostic criteria 4. ability and willingness to understand and comply with the study procedures 5. ability to read, speak and understand english 6. free access to the internet via computer, tablet or smartphone to complete study surveys and also to allow for study team follow-up as needed. exclusion criteria: 1. participation in a clinical intervention study one month prior to screening visit and throughout the study. 2. medically diagnosed with celiac disease, crohn's disease, ulcerative colitis, diverticulitis, inflammatory bowel disease, or clostridium difficile infection by a doctor 3. pregnant or lactating or wish to become pregnant during the period of the study. 4. lack of suitability for participation in the study for any reason as judged by the site investigator or principal investigator.

Keywords: human milk oligosaccharides ibs-c ibs-d ibs-m
avert plus post-market registry

Conditions: Coronary Artery Disease

Summary: the devices used in this observational registry are the osprey medical contrast monitoring system (cms) and the osprey medical avert reflux reduction system. both products have ce mark designations. the purpose of this registry is to evaluate the usability characteristics of the combined osprey medical avert system and the contrast monitoring system during normal clinical use.

this is a prospective, single-center, non-randomized, single arm, observational registry of the avert system used in combination with the contrast monitoring system. patients undergoing manual manifold injection coronary artery imaging for diagnostic or pci procedures that utilize the avert system and the cms will be included in this registry. device use characteristics including, measurement of contrast media volume used, contrast media volume saved by the use of the avert system, evaluation of angiographic image quality, and physician feedback on device features and function will be obtained. all data will be collected on the day of the procedure and there will be no long-term follow-up.

Eligibility criteria:
inclusion criteria: * scheduled for a coronary diagnostic or pci procedure using manual manifold injection with the avert system and cms according to the labeled indications for these devices. * patient consent to participate exclusion criteria: * none
breathing after covid-19

Conditions: Gait; Covid19; Thorax Anomalies

Summary: this research; it will be done to perform thoracic movement analysis of young adult individuals who have survived covid-19 and to compare them with those without a history of covid-19.

this research; it will be done to perform thoracic movement analysis of young adult individuals who have survived covid-19 and to compare them with those without a history of covid-19. individuals' sternal movements using motion analysis sensors; will be recorded in sitting position, standing, and walking. sternal movement of the person; it will be recorded during relaxed breathing and deep breathing. they will also be asked to walk on the treadmill in such a way as to collect at least 500 steps.

Eligibility criteria:
inclusion criteria: * to be voluntary. * have covid-19 illness history. * no covid-19 illness history. * treated by a standard medical treatment (vitamins, blood thinners, anti-viral drugs) exclusion criteria: * have another chronic disease such as systemic, orthopedic or neurologic.
the validation and efficacy of varix trainer as a training device esophagogastroduodenoscopy (a multicenter study)

Conditions: Gastric Varix

Summary: the goal of this exploratory validation study is to compare levels of expertise (or non-expertise) between gi fellows and experts with the varix trainer. the main question it aim to answer is: can the varix trainer distinguish levels of expertise (or non-expertise) between novices and experts for specific skills (torque, small wheel and retroflexion techniques)? does the training with the varix trainer improves these specific skills of gi fellows? participants will do the pre-training test, practicing eight-sessions (each session is approximately 15minutes) and then do the post-training test.


Eligibility criteria:
inclusion criteria: * we enrolled participants from ramathibodi hospital king chulalongkorn memorial hospital siriraj hospital rajavithi hospital vajira hospital nanthana-kriangkrai chotiwattanaphan institute of gastroenterology and hepatology srinagarind hospital 1. expert (\> 1,500 egd) 2. trainees (first and second year fellow) exclusion criteria: * deny to participate in our study

Keywords: endoscopy training, gastroscopy, tip control, motor skill
a trial comparing the pharmacokinetic properties of fast-acting insulin aspart between children, adolescents and adults with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children \[6-11 years\], adolescents \[12-17 years\] and adults \[18-64 years\]) who have diabetes. the blood sugar (glucose) lowering effect of faster aspart will also be investigated after consuming a meal replacement drink. the effects of faster aspart will be compared to the effects of novorapid®.


Eligibility criteria:
inclusion criteria: * male or female aged 6-64 years (both inclusive) at the time of signing informed consent * diagnosed with type 1 diabetes greater than or equal to 12 months prior to the day of screening * body mass index for children and adolescents (male and female) between the 3rd and 97th bmi percentile and for adults less than or equal to 28.0 kg/sqm exclusion criteria: * subject who has donated any blood or plasma in the past month or more than 500 ml within 3 months prior to screening * smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily) * not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period